Lupin is planning to launch around 30 generic products in the US market this year. The company has currently 162 abbreviated new drug applications pending approval with the US Food and Drug Administration (USFDA).
The company is banking on introduction of complex generics and biosimilars in the US, besides continuing focus on exclusive and semi-exclusive products in oral and injectable space to maintain its top five position in the market.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1908.60 |
| Dr. Reddys Labs. | 1366.00 |
| Cipla | 1454.65 |
| Zydus Lifesciences | 1170.85 |
| Lupin | 2512.80 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: